TY - JOUR
T1 - Increased incidence of symptomatic peripheral neuropathy among adults receiving stavudine-versus zidovudine-based antiretroviral regimens in Kenya
AU - McGrath, Christine J.
AU - Njoroge, Julia
AU - John-Stewart, Grace C.
AU - Kohler, Pamela K.
AU - Benki-Nugent, Sarah F.
AU - Thiga, Joan W.
AU - Etyang, Anthony
AU - Chung, Michael H.
N1 - Funding Information:
The Coptic Hope Center for Infectious Diseases is supported by the President’s Emergency Plan for AIDS Relief (PEPFAR) through a cooperative agreement (U62/CCU024512-04) from the US Centers for Disease Control and Prevention (CDC). Christine J. McGrath is supported by the National Institutes of Health (NIH) (TL1RR025016). Other funding sources include a K23 grant (AI065222 to Michael H. Chung), a K24 grant (HD054314 to Grace C. John-Stewart), and support by the NIH funded program, University of Washington Center for AIDS Research (CFAR) (P30 AI027757). We would like to thank the research personnel, clinic staff, and data management teams in Nairobi, Kenya and Seattle, Washington; the Coptic Hope Center for Infectious Diseases for their participation and cooperation.
PY - 2012/6
Y1 - 2012/6
N2 - The incidence of peripheral neuropathy (PN) among adults initiating antiretroviral therapy (ART) containing stavudine (d4T) versus zidovudine (ZDV) is not well described.We compared 1-year incidence between d4T- and ZDV-based regimens in adults initiating ART in a programmatic setting in Kenya. Of 1,848 adults on ART, 1,579 (85 %) initiated d4Tbased and 269 (15%) initiated ZDV-based regimens. One-year incidence of symptomatic PN per 100 person-years was 21.9 (n0236) among d4T users and 6.9 (n07) among ZDV users (P00.0002). D4T was associated with 2.7 greater risk of PN than ZDV (adjusted hazard ratio, 2.7, P00.009). In settings with continued d4T use, such as Africa, the effects of d4T on PN compared to ZDV should be considered when choosing ART regimens.
AB - The incidence of peripheral neuropathy (PN) among adults initiating antiretroviral therapy (ART) containing stavudine (d4T) versus zidovudine (ZDV) is not well described.We compared 1-year incidence between d4T- and ZDV-based regimens in adults initiating ART in a programmatic setting in Kenya. Of 1,848 adults on ART, 1,579 (85 %) initiated d4Tbased and 269 (15%) initiated ZDV-based regimens. One-year incidence of symptomatic PN per 100 person-years was 21.9 (n0236) among d4T users and 6.9 (n07) among ZDV users (P00.0002). D4T was associated with 2.7 greater risk of PN than ZDV (adjusted hazard ratio, 2.7, P00.009). In settings with continued d4T use, such as Africa, the effects of d4T on PN compared to ZDV should be considered when choosing ART regimens.
KW - Africa
KW - Antiretroviral therapy
KW - HIV
KW - Peripheral neuropathy
KW - Toxicity
UR - http://www.scopus.com/inward/record.url?scp=84863709482&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84863709482&partnerID=8YFLogxK
U2 - 10.1007/s13365-012-0098-x
DO - 10.1007/s13365-012-0098-x
M3 - Article
C2 - 22528481
AN - SCOPUS:84863709482
SN - 1355-0284
VL - 18
SP - 200
EP - 204
JO - Journal of neurovirology
JF - Journal of neurovirology
IS - 3
ER -